Amedisys (AMED) Competitors $97.18 -0.49 (-0.50%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$97.16 -0.02 (-0.02%) As of 07/11/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMED vs. DVA, CHE, CRVL, MD, AMN, CCRN, LH, DGX, EHC, and ELANShould you be buying Amedisys stock or one of its competitors? The main competitors of Amedisys include DaVita (DVA), Chemed (CHE), CorVel (CRVL), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), Labcorp (LH), Quest Diagnostics (DGX), Encompass Health (EHC), and Elanco Animal Health (ELAN). Amedisys vs. Its Competitors DaVita Chemed CorVel Pediatrix Medical Group AMN Healthcare Services Cross Country Healthcare Labcorp Quest Diagnostics Encompass Health Elanco Animal Health Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations. Which has more volatility and risk, AMED or DVA? Amedisys has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Do analysts recommend AMED or DVA? Amedisys currently has a consensus target price of $100.75, indicating a potential upside of 3.67%. DaVita has a consensus target price of $164.50, indicating a potential upside of 15.49%. Given DaVita's higher possible upside, analysts clearly believe DaVita is more favorable than Amedisys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amedisys 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25DaVita 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable valuation and earnings, AMED or DVA? DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmedisys$2.37B1.34$43.23M$2.7135.86DaVita$12.82B0.84$936.34M$10.0914.12 Does the media refer more to AMED or DVA? In the previous week, DaVita had 4 more articles in the media than Amedisys. MarketBeat recorded 5 mentions for DaVita and 1 mentions for Amedisys. DaVita's average media sentiment score of 1.14 beat Amedisys' score of -0.01 indicating that DaVita is being referred to more favorably in the news media. Company Overall Sentiment Amedisys Neutral DaVita Positive Is AMED or DVA more profitable? DaVita has a net margin of 6.63% compared to Amedisys' net margin of 3.79%. DaVita's return on equity of 176.11% beat Amedisys' return on equity.Company Net Margins Return on Equity Return on Assets Amedisys3.79% 12.52% 7.01% DaVita 6.63%176.11%4.66% Do institutionals & insiders believe in AMED or DVA? 94.4% of Amedisys shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 2.1% of Amedisys shares are owned by insiders. Comparatively, 2.0% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryDaVita beats Amedisys on 9 of the 15 factors compared between the two stocks. Get Amedisys News Delivered to You Automatically Sign up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMED vs. The Competition Export to ExcelMetricAmedisysMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.19B$3.87B$5.60B$9.10BDividend YieldN/A1.32%5.24%4.00%P/E Ratio35.8635.5827.9620.25Price / Sales1.3495.45429.2099.14Price / Cash15.6723.6037.4658.16Price / Book2.704.328.045.49Net Income$43.23M$189.47M$3.18B$250.27M7 Day Performance1.08%-3.28%3.63%4.75%1 Month Performance-0.05%-6.53%4.04%7.64%1 Year Performance-0.93%-1.25%29.56%16.34% Amedisys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMEDAmedisys2.549 of 5 stars$97.18-0.5%$100.75+3.7%-1.2%$3.19B$2.37B35.8619,000DVADaVita4.4516 of 5 stars$142.71+0.1%$164.50+15.3%+1.6%$10.77B$12.82B14.1476,000Positive NewsCHEChemed4.985 of 5 stars$461.20-2.5%$645.00+39.9%-14.2%$6.75B$2.43B22.4615,695CRVLCorVel1.1717 of 5 stars$100.00-2.8%N/A+11.8%$5.14B$895.59M54.455,075News CoveragePositive NewsMDPediatrix Medical Group2.7875 of 5 stars$13.44-2.5%$16.67+24.0%+82.1%$1.15B$2.01B-13.314,305AMNAMN Healthcare Services4.2409 of 5 stars$21.23-3.1%$32.08+51.1%-57.1%$812.68M$2.98B-4.902,968CCRNCross Country Healthcare3.8971 of 5 stars$12.75-2.0%$17.93+40.6%-11.1%$417.95M$1.34B-24.068,205LHLabcorp4.7169 of 5 stars$257.78-1.6%$276.08+7.1%+20.9%$21.58B$13.01B29.8070,000Trending NewsDividend AnnouncementAnalyst ForecastAnalyst RevisionDGXQuest Diagnostics4.9708 of 5 stars$173.78-1.8%$185.73+6.9%+17.1%$19.40B$9.87B21.9756,000News CoveragePositive NewsAnalyst RevisionEHCEncompass Health4.9521 of 5 stars$119.22+0.2%$127.00+6.5%+38.0%$12.02B$5.37B24.6340,000Positive NewsAnalyst RevisionELANElanco Animal Health1.5011 of 5 stars$14.48-1.1%$15.33+5.9%+9.0%$7.19B$4.44B19.579,000News Coverage Related Companies and Tools Related Companies DVA Competitors CHE Competitors CRVL Competitors MD Competitors AMN Competitors CCRN Competitors LH Competitors DGX Competitors EHC Competitors ELAN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMED) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored"I'm risking my reputation on this"Most people think you need thousands to profit from crypto. But this free book exposes how even small inves...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amedisys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMED Stock Alerts